Genetics in Medicine (2023) 25, 100866

ELSEVIER

Genetics in Medicine
An Official Journal of the ACMG

www.journals.elsevier.com/genetics-in-medicine

ACMG STATEMENT

ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)

David T. Miller[1], Kristy Lee[2], Noura S. Abul-Husn[3,4], Laura M. Amendola[5], Kyle Brothers[6], Wendy K. Chung[7], Michael H. Gollob[8], Adam S. Gordon[9], Steven M. Harrison[10], Ray E. Hershberger[11], Teri E. Klein[12], C. Sue Richards[13], Douglas R. Stewart[14], Christa Lese Martin[15]; on behalf of the ACMG Secondary Findings Working Group[16,*]

ARTICLE INFO

Article history:
Received 10 April 2023
Accepted 12 April 2023
Available online 22 June 2023

Keywords:
Exome sequencing
Genome sequencing
Incidental findings
Secondary findings

Introduction

The American College of Medical Genetics and Genomics (ACMG) previously published guidance for reporting secondary findings (SFs) in the context of clinical exome and genome sequencing.[1-5] The ACMG Secondary Findings Working Group (SFWG) and Board of Directors (BODs) have agreed that the list of recommended genes should now be updated annually, but with an ongoing goal of maintaining this as a minimum list. Reporting of SFs should be considered neither a replacement for indication-based diagnostic clinical genetic testing nor a form of population screening.

Per nomenclature guidance put forth by the ACMG SFWG and approved by the BODs,[2] versioning of the SF list was designed to differentiate major vs minor revisions. Major

The Board of Directors of the American College of Medical Genetics and Genomics approved this statement on February 27, 2023.
*Correspondence: ACMG. *Email address:* documents@acmg.net
Affiliations are at the end of the document.

doi: https://doi.org/10.1016/j.gim.2023.100866

revisions include conceptual changes to the categories or genes/variants in the SF list or the removal/addition of a large number of genes in a single update; these changes are denoted by updating the version number to the next integer (eg, v4.0, v5.0). Minor revisions reflect the addition or removal of 1 or a few genes or variants without any policy change, and they are denoted by an incremental change to the number after the decimal point (eg, v3.1, v3.2).

The current SFWG includes clinical geneticists, molecular and/or cytogenetics clinical laboratory directors, genetic counselors, cardiologists, a bioinformatician, and a bioethicist. The SFWG has met at least monthly via web conferencing to review nomination forms and vote on the inclusion or exclusion of gene-phenotype pairs for the ACMG SF v3.2 list. Details on the nomination and review process have been published.[3]

Internal nominations from SFWG committee members and external nominations were considered for the SF v3.2 list. Internal nominations from committee members included the *CALM1*, *CALM2*, and *CALM3* genes as gene-phenotype pairs with long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia. An external nomination was reviewed for the *ATP7A* gene that is associated with Menkes disease. No nominations were requested by other professional organizations. The final proposed ACMG SF v3.2 list from the SFWG was sent to the ACMG BODs for review and approval in October 2022. Member comments were received in January 2023, and the working group submitted a revision to the Board in February 2023.

Recommendations for the ACMG SF v3.2 List

The overall responsibility of the SFWG is to provide recommendations for a minimum list of gene-phenotype pairs for opportunistic screening to facilitate the identification and/or management of risks for selected genetic disorders through established interventions aimed at preventing or significantly reducing morbidity and mortality.[2] The complete ACMG SF v3.2 list is presented in Table 1 (and is also presented as a spreadsheet in Supplemental Table 1). As shown in Table 2, 3 new genes, *CALM1*, *CALM2*, and *CALM3*, were added to the v3.2 list, with a brief description of the factors considered in adding each of these genes. Only 1 gene, *ATP7A*, was considered for inclusion, but it was ultimately excluded from the v3.2 list (Table 3); *ATP7A* could be reviewed again in the future if new data emerge that are related to either Menkes disease or other phenotypes associated with this gene.

Considerations for Specific Phenotypic Categories

Genes related to cancer phenotypes

Recommended for addition to, or removal from, the SF v3.2 list: None

Genes related to cardiovascular phenotypes

Recommended for addition to the SF v3.2 list: *CALM1*, *CALM2*, and *CALM3*

Cardiovascular genes have been represented on the SF list since its inception because of the morbidity and mortality of heart failure and sudden cardiac death, which can both be treated or prevented with well-established interventions.[9,10]

For version 3.2, 3 additional genes (*CALM1*, *CALM2*, and *CALM3*) were reviewed. These genes cause predisposition to LQTS, and the available evidence supports a similar or greater risk of morbidity and mortality compared with other sudden cardiac death genes that are already included in the previous versions of the SF list. The 3 calmodulin genes (*CALM1*, *CALM2*, and *CALM3*) are located on different chromosomes, but they encode identical 149 amino acid proteins. All 3 were previously classified by ClinGen as having definitive evidence for LQTS with atypical features such as presentation in infancy or early childhood and with functional heart block and severe QT prolongation.[11]

A member comment suggested updating the nomenclature that is used for reportable variants in the *TTN* gene, as outlined in the Table 1 footnote. Because the exact disease mechanisms are still being elucidated, it was suggested to refer to *TTN* truncating variants as *TTN*tv, instead of loss-of-function variants. This update has been included as part of the ACMG SF v3.2 list. A member comment also requested additional guidance regarding which truncating variants in the Titin gene (*TTN*tv) should be reported as SFs. Specifically, a suggestion was made to "add specific details to include consideration of the cardiac isoforms/transcripts, highly expressed exons, and established regions with enrichment for *TTN*tv and dilated cardiomyopathy (DCM)."

We currently recommend that only frameshift and nonsense variants, and variants known to affect the splicing of *TTN* exons with high proportion spliced-in, be evaluated for pathogenicity and returned as SFs if classified as pathogenic and likely pathogenic.[6-8] This update has been included as part of the ACMG SF v3.2 list and provided as a footnote in Table 1. We anticipate that additional guidance may be provided from experts in the field over time and defer to further guidance that may be published in the future (Note "variants known to impact splicing" refers to variants affecting the invariable +/− 1, 2 positions and other coding or noncoding variants with demonstrated impact.).

Genes related to inborn errors of metabolism phenotypes

Nominated for addition to the SF list: *ATP7A*

The working group carefully considered the nomination of *ATP7A* as a gene-disease pair for Menkes disease. Menkes disease is infantile onset, has a high morbidity rate, the causative gene (*ATP7A*) can be assessed by standard exome sequencing, and there is a potential treatment. To further evaluate this gene-phenotype pair, we consulted an

Table 1 ACMG SF v3.2 gene and associated phenotypes recommended for return as secondary findings from clinical exome and genome sequencing

Phenotype	ACMG SF List Version	MIM Disorder	Gene	Inheritance	Variants to Report[a]
Genes related to cancer phenotypes					
Familial adenomatous polyposis	1.0	175100	*APC*	AD	All P and LP
Familial medullary thyroid cancer/multiple endocrine neoplasia 2	1.0	155240	*RET*	AD	All P and LP
		171400			
		162300			
Hereditary breast and/or ovarian cancer	1.0	604370	*BRCA1*	AD	All P and LP
	1.0	612555	*BRCA2*		
	3.0	114480	*PALB2*		
Hereditary paraganglioma-pheochromocytoma syndrome	1.0	168000	*SDHD*	AD	All P and LP
	1.0	601650	*SDHAF2*		
	1.0	605373	*SDHC*		
	1.0	115310	*SDHB*		
	3.0	171300	*MAX*		
	3.0	171300	*TMEM127*		
Juvenile polyposis syndrome	2.0	174900	*BMPR1A*	AD	All P and LP
Juvenile polyposis syndrome/hereditary hemorrhagic telangiectasia syndrome	2.0	175050	*SMAD4*	AD	All P and LP
Li-Fraumeni syndrome	1.0	151623	*TP53*	AD	All P and LP
Lynch syndrome (hereditary nonpolyposis colorectal cancer)	1.0	609310	*MLH1*	AD	All P and LP
		120435	*MSH2*		
		614350	*MSH6*		
		614337	*PMS2*		
Multiple endocrine neoplasia type 1	1.0	131100	*MEN1*	AD	All P and LP
MUTYH-associated polyposis	1.0	608456	*MUTYH*	AR	P and LP (2 variants)
NF2-related schwannomatosis	1.0	101000	*NF2*	AD	All P and LP
Peutz-Jeghers syndrome	1.0	175200	*STK11*	AD	All P and LP
PTEN hamartoma tumor syndrome	1.0	158350	*PTEN*	AD	All P and LP
Retinoblastoma	1.0	180200	*RB1*	AD	All P and LP
Tuberous sclerosis complex	1.0	191100	*TSC1*	AD	All P and LP
	1.0	613254	*TSC2*		
von Hippel-Lindau syndrome	1.0	193300	*VHL*	AD	All P and LP
WT1-related Wilms tumor	1.0	194070	*WT1*	AD	All P and LP
Genes related to cardiovascular phenotypes					
Aortopathies	1.0	154700	*FBN1*	AD	All P and LP
	1.0	609192	*TGFBR1*		
	1.0	610168	*TGFBR2*		
	1.0	613795	*SMAD3*		
	1.0	611788	*ACTA2*		
	1.0	132900	*MYH11*		
Arrhythmogenic right ventricular cardiomyopathy (a subcategory of arrhythmogenic cardiomyopathy)	1.0	609040	*PKP2*	AD	All P and LP
	1.0	607450	*DSP*[b]		
	1.0	610476	*DSC2*		
	1.0	604400	*TMEM43*		
	1.0	610193	*DSG2*		
Catecholaminergic polymorphic ventricular tachycardia	1.0	604772	*RYR2*	AD	All P and LP
	3.0	611938	*CASQ2*	AR	P and LP (2 variants)
	3.0	615441	*TRDN*[c]	AR	
DCM	1.0	601494	*TNNT2*[d]	AD	All P and LP (See text)
	1.0	115200	*LMNA*[e]		
	3.0	617047	*FLNC*[d]		
	3.0	604145	*TTN*[f]		
	3.1	613881	*BAG3*		
	3.1	604765	*DES*		
	3.1	613172	*RBM20*		
	3.1	611879	*TNNC1*		
Ehlers-Danlos syndrome, vascular type	1.0	130050	*COL3A1*	AD	All P and LP

(continued)

Table 1 Continued

Phenotype	ACMG SF List Version	MIM Disorder	Gene	Inheritance	Variants to Report[a]
Familial hypercholesterolemia	1.0	143890	*LDLR*	SD	All P and LP
	1.0	144010	*APOB*	AD	
	1.0	603776	*PCSK9*	AD	
HCM[g]	1.0	192600	*MYH7*[b]	AD	All P and LP
	1.0	115197	*MYBPC3*		
	1.0	613690	*TNNI3*		
	1.0	115196	*TPM1*		
	1.0	608751	*MYL3*		
	1.0	612098	*ACTC1*		
	1.0	600858	*PRKAG2*		
	1.0	608758	*MYL2*		
LQTS types 1 and 2	1.0	192500	*KCNQ1*	AD	All P and LP
	1.0	613688	*KCNH2*		
LQTS3; Brugada syndrome	1.0	603830, 601144	*SCN5A*[b]	AD	All P and LP
LQTS types 14-16	3.2	616247	*CALM1*[g]	AD	All P and LP
		616249	*CALM2*[g]	AD	
		618782	*CALM3*[g]	AD	
Genes related to inborn errors of metabolism phenotypes					
Biotinidase deficiency	3.0	253260	*BTD*	AR	P and LP (2 variants)
Fabry disease	1.0	301500	*GLA*[h]	XL	All hemi, het, homozygous P and LP
Ornithine transcarbamylase deficiency	2.0	311250	*OTC*	XL	All hemi, het, homozygous P and LP
Pompe disease	3.0	232300	*GAA*	AR	P and LP (2 variants)
Genes related to miscellaneous phenotypes					
Hereditary hemochromatosis	3.0	235200	*HFE*	AR	*HFE* p.C282Y[i] homozygotes only
Hereditary hemorrhagic telangiectasia	3.0	600376	*ACVRL1*	AD	All P and LP
	3.0	187300	*ENG*		
Malignant hyperthermia	1.0	145600	*RYR1*[j]	AD	All P and LP
	1.0	601887	*CACNA1S*		
Maturity-onset of diabetes of the young	3.0	600496	*HNF1A*	AD	All P and LP
RPE65-related retinopathy	3.0	204100, 613794	*RPE65*	AR	P and LP (2 variants)
Wilson disease	2.0	277900	*ATP7B*	AR	P and LP (2 variants)
Hereditary TTR amyloidosis	3.1	105210	*TTR*	AD	All P and LP

AD, autosomal dominant; *AR*, autosomal recessive; *DCM*, dilated cardiomyopathy; *HCM*, hypertrophic cardiomyopathy; *hemi*, hemizygous; *het*, heterozygous; *LP*, likely pathogenic; *LQTS*, long QT syndrome; *MIM*, Mendelian Inheritance of Man; *P*, pathogenic; *pLOF*, putative loss-of-function; *SD*, semidominant; *SF*, secondary finding; *TTR*, transthyretin; *XL*, X-linked.

[a]Variants within genes associated with autosomal dominant phenotypes should be classified as P or LP to be reportable. Genes associated with phenotypes inherited in an autosomal recessive fashion would need 2 LP and/or P variants to meet the threshold for reporting even when phase is undetermined, as follow-up family variant testing can often resolve phase. Finally, P and LP variants within genes associated with X-linked phenotypes that are apparently hemizygous, heterozygous, or homozygous should be reported, as often heterozygous females can have adverse medical events at a reasonable frequency and treatment or amelioration of disease is available. Variants of uncertain significance should not be reported in any gene.

[b]Also associated with DCM as a primary disease.

[c]Also associated with long QT syndrome.

[d]Also associated with HCM.

[e]P/LP *LMNA* variants that have any case level phenotype evidence of association with cardiac disease (eg, DCM, arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and/or arrhythmia) should be reported, whereas previously reported P/LP missense variants never associated with cardiac disease should not be reported. Also, for novel pLOF variants that reach LP without case observations, these variants should be reported given the general association of pLOF *LMNA* variants with cardiac disease and the evidence summary should include mention of the spectrum of phenotypes that may be observed with LMNA pLOF variation.

[f]We currently recommend that only frameshift and nonsense variants, and variants known to impact the splicing of *TTN* exons with high PSI (see references[6-8]), be evaluated for pathogenicity and returned as secondary findings if classified as P/LP.

[g]Also associated with catecholaminergic polymorphic ventricular tachycardia.

[h]Gene also applies to the cardiovascular category.

[i]Transcript for the *HFE* gene is NM_000410.3.

[j]*RYR1* also causes a neuromuscular phenotype. Only P/LP variants associated with malignant hyperthermia should be reported as a secondary finding.

Table 2 New gene/phenotype pairs for SF v3.2 list

Gene/Phenotype	Additional Comments
Genes related to cardiovascular phenotypes	
CALM1/long QT syndrome	Similar prevalence/penetrance rates to other SCD genes previously on ACMG SF list
CALM2/long QT syndrome	Similar prevalence/penetrance rates to other SCD genes previously on ACMG SF list
CALM3/long QT syndrome	Similar prevalence/penetrance rates to other SCD genes previously on ACMG SF list

ACMG, American College of Medical Genetics and Genomics; *SCD*, sudden cardiac death; *SF*, secondary findings.

ad hoc expert for feedback about available treatment options. After careful consideration, we determined that there was insufficient evidence that the only available treatment, subcutaneous injections of copper histidinate, is efficacious. In addition, there was concern that this treatment is potentially toxic.[12] We also noted that pathogenic and likely pathogenic variants would likely be identified as a primary (diagnostic) result as opposed to an SF.

Pathogenic variants in *ATP7A* can also result in occipital horn syndrome (OHS) and *ATP7A*-related distal motor neuropathy (DMN). OHS and *ATP7A*-related DMN are childhood or adult onset and hence could be considered SFs, but this gene was only reviewed by the working group in relation to Menkes disease. Although the other conditions were not specifically reviewed, the concern about insufficient evidence for efficacy of copper histidinate would also apply to OHS and *ATP7A*-related DMN.

Conclusions

With the 2021 publication of the SF policy statements for reporting of SFs and the SF v3.0 gene list,[3,4] the SFWG created a mechanism for separating updates to the policy and principles for SF reporting from updates to the SF gene list. This dual publication approach facilitates more frequent updates to the actual SF gene list. Going forward, we foresee updates to the general policy only as needed, likely every few years. In contrast, updates to the gene list will be targeted to occur on an annual basis and to be published at approximately the same time each year so that all stakeholders can expect an update and be prepared to revise laboratory and reporting processes. We recognize that clinical laboratories must integrate updates into their workflow, and clinicians must familiarize themselves with the genes on the list for the purposes of genetic counseling and informed consent. Our intention is to publish an updated list each year in January.

Table 3 Genes not selected for SF v3.2 list

Gene/Phenotype	Category	Additional Comments
ATP7A/Menkes disease	Inborn errors of metabolism	Lack of demonstrated effectiveness and possible toxicity of the available treatment

SF, secondary findings.

The SFWG will continue to review this list of actionable genes, and new nominations, throughout the course of the year. We also wish to remind the community that ACMG members may nominate genes or variants to be added to, or removed from, the list based on an evolving evidence base and/or evolving standards in the practice of medicine. We will also consider nominations submitted through representatives of other professional organizations. Nomination forms can be found on the ACMG website (https://form.jotform.com/203275021199048). We hope that the detailed descriptions of our decision process during the preparation of this update will help the community better understand the types of genes and variants that we consider appropriate for this list to guide nominations going forward.

Acknowledgments

The authors are grateful to the ClinGen Actionability Working Group for their evaluations of genes that the authors reviewed.

Conflict of Interest

Funding and support listed here did not support development of this document unless included in the Acknowledgments section. N.S.A.-H. is an equity holder of 23andMe; serves as a scientific advisory board member for Allelica; received personal fees from Genentech, Allelica, and 23andMe; received research funding from Akcea; and was previously employed by Regeneron Pharmaceuticals. W.K.C. is a member of the scientific advisory board of Regeneron Genetics Center. D.T.M. has received an honorarium from Ambry Genetics. D.R.S. is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, Rockville, MD, and also performs contract clinical telehealth services for Genome Medical, Inc., in accordance with relevant National Cancer Institute ethics policies. All other authors declare no conflicts of interest.

Additional Information

The online version of this article (https://doi.org/10.1016/j.gim.2023.100866) contains supplementary material, which is available to authorized users.

Affiliations

[1]Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA; [2]Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC;

[3]Department of Medicine, Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY; [4]23andMe, Inc., Sunnyvale, CA; [5]Illumina, Inc., San Diego, CA; [6]Department of Pediatrics, University of Louisville, Louisville, KY; [7]Departments of Pediatrics and Medicine, Columbia University, New York, NY; [8]Division of Cardiology, Department of Physiology, University of Toronto, Toronto, ON, Canada; [9]Department of Pharmacology, Center for Genetic Medicine, Northwestern University, Chicago, IL; [10]Ambry Genetics, Aliso Viejo, CA; [11]Divisions of Human Genetics and Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University, Columbus, OH; [12]Departments of Biomedical Data Science and Medicine, Stanford University, Stanford, CA; [13]Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR; [14]Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD; [15]Autism & Developmental Medicine Institute, Geisinger, Danville, PA; [16]American College of Medical Genetics and Genomics, Bethesda, MD

References

1. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med*. 2013;15(7):565-574. http://doi.org/10.1038/gim.2013.73
2. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. *Genet Med*. 2017;19(2):249-255. http://doi.org/10.1038/gim.2016.190
3. Miller DT, Lee K, Gordon AS, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021;23(8):1391-1398. http://doi.org/10.1038/s41436-021-01171-4
4. Miller DT, Lee K, Chung WK, et al. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021;23(8):1381-1390. http://doi.org/10.1038/s41436-021-01172-3
5. Miller DT, Lee K, Abul-Husn NS, et al. ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2022;24(7):1407-1414. http://doi.org/10.1016/j.gim.2022.04.006
6. Roberts AM, Ware JS, Herman DS, et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. *Sci Transl Med*. 2015;7(270):270ra6. http://doi.org/10.1126/scitranslmed.3010134
7. Schafer S, de Marvao A, Adami E, et al. Titin-truncating variants affect heart function in disease cohorts and the general population. *Nat Genet*. 2017;49(1):46-53. http://doi.org/10.1038/ng.3719
8. Cardiovascular Genetics and Genomics Group. Titin variants in dilated cardiomyopathy. Accessed April 5, 2023. http://cardiodb.org/titin
9. Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline. *J Card Fail*. 2018;24(5):281-302. http://doi.org/10.1016/j.cardfail.2018.03.004
10. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2018;138(13):e272-e391. http://doi.org/10.1161/CIR.0000000000000549
11. Adler A, Novelli V, Amin AS, et al. An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome. *Circulation*. 2020;141(6):418-428. http://doi.org/10.1161/CIRCULATIONAHA.119.043132
12. Natera-de Benito D, Sola A, Sousa PR, et al. Copper toxicity associated with an ATP7A-related complex phenotype. *Pediatr Neurol*. 2021;119:40-44. http://doi.org/10.1016/j.pediatrneurol.2021.03.005

"The ACMG Secondary Findings v3.2 list is provided here in spreadsheet format for content searchability, but has not been validated for clinical testing pipeline use to ensure the accuracy of data (e.g. gene symbols, OMIM numbers, etc)."

Gene	Gene MIM	Disease/Phentyope	Disorder MIM	Phenotype Category	Inheritance	SF List Version	Variants to report
ACTA2	102620	Familial thoracic aortic aneurysm	611788	Cardiovascular	AD	1.0	All P and LP
ACTC1	102540	Hypertrophic cardiomyopathy	612098	Cardiovascular	AD	1.0	All P and LP
ACVRL1	601284	Hereditary hemorrhagic telangiectasia	600376	Miscellaneous	AD	3.0	All P and LP
APC	611731	Familial adenomatous polyposis	175100	Cancer	AD	1.0	All P and LP
APOB	107730	Familial hypercholesterolemia	144010	Cardiovascular	AD	1.0	All P and LP
ATP7B	606882	Wilson disease	277900	Miscellaneous	AR	2.0	P and LP (2 variants)
BAG3	603883	Dilated cardiomyopathy	613881	Cardiovascular	AD	3.1	All P and LP
BAG3	603883	Myofibrillar myopathy	612954	Cardiovascular	AD	3.1	All P and LP
BMPR1A	601299	Juvenile polyposis syndrome	174900	Cancer	AD	1.0	All P and LP
BRCA1	113705	Hereditary breast and ovarian cancer	604370	Cancer	AD	1.0	All P and LP
BRCA2	600185	Hereditary breast and ovarian cancer	612555	Cancer	AD	1.0	All P and LP
BTD	609019	Biotinidase deficiency	253260	Metabolic	AR	3.0	P and LP (2 variants)
CACNA1S	114208	Malignant hyperthermia	601887	Miscellaneous	AD	1.0	All P and LP
CALM1	114180	Long-QT syndrome type 14	616247	Cardiovascular	AD	3.2	All P and LP
CALM1	114180	Catecholaminergic polymorphic ventricular tachycardia	614916	Cardiovascular	AD	3.2	All P and LP
CALM2	114182	Long-QT syndrome type 15	616249	Cardiovascular	AD	3.2	All P and LP
CALM2	114182	Catecholaminergic polymorphic ventricular tachycardia	616249	Cardiovascular	AD	3.2	All P and LP
CALM3	114183	Long-QT syndrome type 16	618782	Cardiovascular	AD	3.2	All P and LP
CALM3	114183	Catecholaminergic polymorphic ventricular tachycardia	618782	Cardiovascular	AD	3.2	All P and LP
CASQ2	114251	Catecholaminergic polymorphic ventricular tachycardia	611938	Cardiovascular	AR	3.0	P and LP (2 variants)
COL3A1	120180	Ehlers-Danlos syndrome, vascular type	130050	Cardiovascular	AD	1.0	All P and LP
DES	125660	Dliated cardiomyopathy	604765	Cardiovascular	AD	3.1	All P and LP
DES	125660	Myofibrillar myopathy	601419	Cardiovascular	AD	3.1	All P and LP
DSC2	125645	Arrhythmogenic right ventricular cardiomyopathy	610476	Cardiovascular	AD	1.0	All P and LP
DSG2	125671	Arrhythmogenic right ventricular cardiomyopathy	610193	Cardiovascular	AD	1.0	All P and LP
DSP	125647	Arrhythmogenic right ventricular cardiomyopathy	607450	Cardiovascular	AD	1.0	All P and LP
DSP	125647	Dilated cardiomyopathy	615821	Cardiovascular	AD	1.0	All P and LP
ENG	131195	Hereditary hemorrhagic telangiectasia	187300	Miscellaneous	AD	3.0	All P and LP
FBN1	134797	Marfan syndrome	154700	Cardiovascular	AD	1.0	All P and LP
FLNC	102565	Dilated cardiomyopathy	n/a	Cardiovascular	AD	3.0	All P and LP
FLNC	102565	Hypertrophic cardiomyopathy	617047	Cardiovascular	AD	3.0	All P and LP
FLNC	102565	Myofibrillar myopathy	609524	Cardiovascular	AD	3.0	All P and LP
GAA	606800	Pompe disease	232300	Metabolic	AR	3.0	P and LP (2 variants)
GLA	300644	Fabry disease	301500	Cardiovascular Metabolic	XL	1.0	All hemi, het, homozygous P and LP
HFE	613609	Hereditary hemochromatosis (c.845G>A; p.C282Y homozygotes only)	235200	Miscellaneous	AR	3.0	p.C282Y homozygotes only
HNF1A	142410	Maturity-Onset of Diabetes of the Young	600496	Miscellaneous	AD	3.0	All P and LP
KCNH2	152427	Long-QT syndrome type 2	613688	Cardiovascular	AD	1.0	All P and LP
KCNQ1	607542	Long-QT syndrome type 1	192500	Cardiovascular	AD	1.0	All P and LP
LDLR	606945	Familial hypercholesterolemia	143890	Cardiovascular	AD	1.0	All P and LP
LMNA	150330	Dilated cardiomyopathy	115200	Cardiovascular	AD	1.0	All P and LP
MAX	154950	Hereditary paraganglioma-pheochromocytoma syndrome	171300	Cancer	AD	3.0	All P and LP
MEN1	613733	Multiple endocrine neoplasia type 1	131100	Cancer	AD	1.0	All P and LP
MLH1	120436	Lynch syndrome	609310	Cancer	AD	1.0	All P and LP
MSH2	609309	Lynch syndrome	120435	Cancer	AD	1.0	All P and LP
MSH6	600678	Lynch syndrome	614350	Cancer	AD	1.0	All P and LP
MUTYH	604933	*MUTYH* -associated polyposis	608456	Cancer	AR	1.0	P and LP (2 variants)
MYBPC3	600958	Hypertrophic cardiomyopathy	115197	Cardiovascular	AD	1.0	All P and LP

MYH11	160745	Familial thoracic aortic aneurysm	132900	Cardiovascular	AD	1.0	All P and LP
MYH7	160760	Hypertrophic cardiomyopathy	192600	Cardiovascular	AD	1.0	All P and LP
MYH7	160760	Dilated cardiomyopathy	613426	Cardiovascular	AD	1.0	All P and LP
MYL2	160781	Hypertrophic cardiomyopathy	608758	Cardiovascular	AD	1.0	All P and LP
MYL3	160790	Hypertrophic cardiomyopathy	608751	Cardiovascular	AD	1.0	All P and LP
NF2	607379	*NF2* -related schwannomatosis	101000	Cancer	AD	1.0	All P and LP
OTC	300461	Ornithine transcarbamylase deficiency	311250	Metabolic	XL	2.0	All hemi, het, homozygous P and LP
PALB2	610355	Hereditary breast cancer	114480	Cancer	AD	3.0	All P and LP
PCSK9	607786	Familial hypercholesterolemia	603776	Cardiovascular	AD	1.0	All P and LP
PKP2	602861	Arrhythmogenic right ventricular cardiomyopathy	609040	Cardiovascular	AD	1.0	All P and LP
PMS2	600259	Lynch syndrome	614337	Cancer	AD	1.0	All P and LP
PRKAG2	602743	Hypertrophic cardiomyopathy	600858	Cardiovascular Metabolic	AD	1.0	All P and LP
PTEN	601728	*PTEN* hamartoma tumor syndrome	158350	Cancer	AD	1.0	All P and LP
RB1	614041	Retinoblastoma	180200	Cancer	AD	1.0	All P and LP
RBM20	613171	Dliated cardiomyopathy	613172	Cardiovascular	AD	3.1	All P and LP
RET	164761	Familial medullary thyroid cancer	155240	Cancer	AD	1.0	All P and LP
RET	164761	Multiple endocrine neoplasia type 2A	171400	Cancer	AD	1.0	All P and LP
RET	164761	Multiple endocrine neoplasia type 2B	162300	Cancer	AD	1.0	All P and LP
RPE65	180069	*RPE65* -related retinopathy	204100, 613794	Miscellaneous	AR	3.0	P and LP (2 variants)
RYR1	180901	Malignant hyperthermia	145600	Miscellaneous	AD	1.0	All P and LP
RYR2	180902	Catecholaminergic polymorphic ventricular tachycardia	604772	Cardiovascular	AD	1.0	All P and LP
SCN5A	600163	Long QT syndrome type 3	603830	Cardiovascular	AD	1.0	All P and LP
SCN5A	600163	Brugada syndrome	601144	Cardiovascular	AD	1.0	All P and LP
SCN5A	600163	Dilated cardiomyopathy	601154	Cardiovascular	AD	1.0	All P and LP
SDHAF2	613019	Hereditary paraganglioma-pheochromocytoma syndrome	601650	Cancer	AD	1.0	All P and LP
SDHB	185470	Hereditary paraganglioma-pheochromocytoma syndrome	115310, 171300	Cancer	AD	1.0	All P and LP
SDHC	602413	Hereditary paraganglioma-pheochromocytoma syndrome	605373	Cancer	AD	1.0	All P and LP
SDHD	602690	Hereditary paraganglioma-pheochromocytoma syndrome	168000, 171300	Cancer	AD	1.0	All P and LP
SMAD3	603109	Loeys-Dietz syndrome	613795	Cardiovascular	AD	1.0	All P and LP
SMAD4	600993	Juvenile polyposis syndrome	174900	Cancer	AD	1.0	All P and LP
SMAD4	600993	Hereditary hemorrhagic telangiectasia	175050	Miscellaneous	AD	1.0	All P and LP
STK11	602216	Peutz-Jeghers syndrome	175200	Cancer	AD	1.0	All P and LP
TGFBR1	190181	Loeys-Dietz syndrome	609192	Cardiovascular	AD	1.0	All P and LP
TGFBR2	190182	Loeys-Dietz syndrome	610168	Cardiovascular	AD	1.0	All P and LP
TMEM127	613403	Hereditary paraganglioma-pheochromocytoma syndrome	171300	Cancer	AD	3.0	All P and LP
TMEM43	612048	Arrhythmogenic right ventricular cardiomyopathy	604400	Cardiovascular	AD	1.0	All P and LP
TNNC1	191040	Dilated cardiomyopathy	611879	Cardiovascular	AD	3.1	All P and LP
TNNI3	191044	Hypertrophic cardiomyopathy	613690	Cardiovascular	AD	1.0	All P and LP
TNNT2	191045	Dilated cardiomyopathy	601494	Cardiovascular	AD	1.0	All P and LP
TNNT2	191045	Hypertrophic cardiomyopathy	115195	Cardiovascular	AD	1.0	All P and LP
TP53	191170	Li-Fraumeni syndrome	151623	Cancer	AD	1.0	All P and LP
TPM1	191010	Hypertrophic cardiomyopathy	115196	Cardiovascular	AD	1.0	All P and LP
TRDN	603283	Catecholaminergic polymorphic ventricular tachycardia	615441	Cardiovascular	AR	3.0	All P and LP
TRDN	603283	Long QT syndrome	n/a	Cardiovascular	AR	3.0	All P and LP
TSC1	605284	Tuberous sclerosis complex	191100	Cancer	AD	1.0	All P and LP
TSC2	191092	Tuberous sclerosis complex	613254	Cancer	AD	1.0	All P and LP
TTN	188840	Dilated cardiomyopathy (truncating variants only)	604145	Cardiovascular	AD	3.0	P and LP (truncating variants only)
TTR	176300	Hereditary transthyretin-related amyloidosis	105210	Miscellaneous	AD	3.1	All P and LP

VHL	608537	Von Hippel-Lindau syndrome	193300	Cancer	AD	1.0	All P and LP
WT1	607102	*WT1* -related Wilms tumor	194070	Cancer	AD	1.0	All P and LP